Prognostic Factors and Outcomes of Early-Stage Hodgkin’s Lymphoma: Multi-Institutional Data From South India

被引:0
|
作者
Lakshmi Sandhya Singuluri
Perumal Kalaiyarasi Jayachandran
Luxitaa Goenka
Praveen Kumar Shenoy
Krishna Kumar Rathnam
Arun Seshachalam
Nikita Mehra
Mummoorthy Ram Kumar
Murugan Mangai Suseela
Vineetha Raghavan
Chandran K. Nair
Biswajit Dubashi
Manikandan Dhanushkodi
Prasanth Ganesan
机构
[1] Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER),Department of Medical Oncology
[2] Cancer Institute (WIA),Department of Medical Oncology
[3] Malabar Cancer Center,Department of Clinical Hematology and Medical Oncology
[4] Madurai Meenakshi Mission Hospital and Research Center,Department of Medical Oncology
[5] GVN Hospital,Department of Medical Oncology
关键词
Early stage Hodgkin's Lymphoma; Survival, Prognostic factors; Chemotherapy; Radiation; India;
D O I
暂无
中图分类号
学科分类号
摘要
Early-stage Hodgkin's lymphoma (ESHL) is highly curable, usually with a combination of chemotherapy and radiation. Real-world data may show differences in survival and prognostic factors when compared to clinical trials. There is limited published literature on ESHL from India. The data on the baseline characters, treatment, and outcomes of patients with ESHL (stage IA, IB, and IIA) were obtained from five institutions' medical records and entered in a common database. Event-free survival (EFS) and overall survival (OS) were estimated using the Kaplan Meier method, and cox-regression analysis was used to identify prognostic factors. There were 258 patients [median age was 37 (18–75) years; [males:160 (62%); stage I: 41%; B symptoms: 17 (6%); bulky disease:19 (15%)] treated between 2000 and 2020 who were evaluable. The common chemotherapies used were ABVD [N = 180 (70%)], COPP-ABVD hybrid [N = 52 (21%)], and COPP [N = 14 (5%)]. Median number of cycles were 4 (2–8) and 93 (47%) received radiation at end of treatment. After a median follow-up of 60 months, the 5 years EFS was 87% and OS was 92%. On multivariate analysis, the following factors adversely affected the EFS: Male gender [hazard ratio (HR) = 2.23, P = 0.02] and Hemoglobin < 10.5g/dL [hazard ration (HR) = 2.20, P = 0.02], and the following adversely affected the OS: Hemoglobin < 10.5g/dL [hazard ratio (HR) = 4.05, P = 0.001], Male gender [hazard ratio (HR) = 3.59, P = 0.004], Stage 2 [hazard ratio (HR) = 2.65, P = 0.002] and ECOG PS (2–3) [hazard ratio (HR) = 3.35, P = 0.01]. Using the hemoglobin, stage and gender a 3-item prognostic score could identify patients with very good outcomes (score 0; 5 years OS:100%) and poor outcomes (score 3; 5 years OS; 49%). This is one of the first multi-center real-world data exclusively focusing on ESHL from India. Though the survival of the entire population was good, there are subsets of patients who have poor outcomes, which may be identified using simple parameters. These parameters need validation in a larger dataset.
引用
收藏
页码:237 / 245
页数:8
相关论文
共 50 条
  • [1] Prognostic Factors and Outcomes of Early-Stage Hodgkin's Lymphoma: Multi-Institutional Data From South India
    Singuluri, Lakshmi Sandhya
    Jayachandran, Perumal Kalaiyarasi
    Goenka, Luxitaa
    Shenoy, Praveen Kumar
    Rathnam, Krishna Kumar
    Seshachalam, Arun
    Mehra, Nikita
    Kumar, Mummoorthy Ram
    Suseela, Murugan Mangai
    Raghavan, Vineetha
    Nair, Chandran K.
    Dubashi, Biswajit
    Dhanushkodi, Manikandan
    Ganesan, Prasanth
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 237 - 245
  • [2] Prognostic factors in early-stage Hodgkin's disease
    Sarris, AH
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 411 - 412
  • [3] Prognostic factors in early-stage Hodgkin's disease - In reply
    Colonna, P
    Andrieu, JM
    Jais, JP
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 412 - 412
  • [4] Definitive SBRT in early-stage HCC: an Australian multi-institutional review of outcomes
    Liu, H.
    Lee, Y. Y.
    Sridharan, S.
    Wang, W.
    Khor, R.
    Chu, J.
    Oar, A.
    Choong, E. S.
    Le, H.
    Shanker, M.
    Wigg, A.
    Stuart, K.
    Pryor, D.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S742 - S743
  • [5] Imaging in Early-Stage Hodgkin's Lymphoma
    Juweid, Malik E.
    Vose, Julie M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10): : 962 - 962
  • [6] Early-Stage Hodgkin's Lymphoma.
    Bibas, Michele
    Antinori, Andrea
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23): : 2267 - 2267
  • [7] Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions
    Klimm, B.
    Goergen, H.
    Fuchs, M.
    von Tresckow, B.
    Boell, B.
    Meissner, J.
    Glunz, A.
    Diehl, V.
    Eich, H. T.
    Engert, A.
    Borchmann, P.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3070 - 3076
  • [8] Controversies in the Treatment of Early-Stage Hodgkin's Lymphoma
    Longo, Dan L.
    Armitage, James O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17): : 1667 - 1669
  • [9] Early-Stage Hodgkin's Lymphoma: In Pursuit of Perfection
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 895 - 896
  • [10] Treatment options for early-stage Hodgkin's lymphoma
    Venkatesan, Priya
    LANCET ONCOLOGY, 2017, 18 (06): : E304 - E304